Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Renske C. F. Hebing
Efficacious Transition From Reference Infliximab to Biosimilar Infliximab in Clinical Practice
International Journal of Rheumatic Diseases
Rheumatology
Related publications
PF-06438179/GP1111: An Infliximab Biosimilar
BioDrugs
Medicine
Biotechnology
Pharmacology
THU0218 the Efficacy and Drug Survival of the Biosimilar Infliximab (CT-P13) Compared to the Original Reference Infliximab in Inflammatory Rheumatic Diseases; Results From the Turkbio Registry
Switching Maintenance Infliximab Therapy to Biosimilar-Infliximab Does Not Lead to Significant Changes in Health-Related Quality of Life and Clinical Outcomes in Inflammatory Bowel Disease Patients
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Comparative Clinical Efficacy and Safety of the Proposed Biosimilar ABP 710 With Infliximab Reference Product in Patients With Rheumatoid Arthritis
Arthritis Research & Therapy
Crystal Structures of PF-06438179/GP1111, an Infliximab Biosimilar
BioDrugs
Medicine
Biotechnology
Pharmacology
Letter: Is There a Role for Infliximab Biosimilar in Patients With Inflammatory Bowel Disease With Secondary Loss of Response to Infliximab Innovator?
Alimentary Pharmacology and Therapeutics
Hepatology
Pharmacology
Gastroenterology
Pregnancy Outcomes in Women With Inflammatory Bowel Disease Treated With Biosimilar Infliximab
Gastroenterologie a Hepatologie
Hepatology
Gastroenterology
AB0389 the Immunogenicity of Branded and Biosimilar Infliximab in Rheumatoid Arthritis According to Th9-Related Responses
Patient Perspectives on Switching From Infliximab to Infliximab‐dyyb in Patients With Rheumatologic Diseases in the United States
ACR Open Rheumatology
